[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645480":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":165,"collaborators":167,"id":171,"slug":172,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":173,"sex":179,"minAge":180,"maxAge":22,"enrollmentInfo":181,"targetDuration":22,"studyType":184,"phases":185,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":48,"whyStopped":22,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},{"fullName":5,"class":6},"Capsicure, LLC","NETWORK",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"IP1: Membrane Wrap - Hydro","EXPERIMENTAL","The study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 147 in wound type.)",[13],"Device: IP 1: Membrane Wrap - Hydro",{"label":15,"type":10,"description":16,"interventionNames":17},"IP2: Microlyte®","This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 147 in wound type.)",[18],"Device: Microlyte®",{"label":20,"type":21,"description":16,"interventionNames":22},"Standard of Care","NO_INTERVENTION",null,[24,31],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","Microlyte®","IP 2: Microlyte® is a sterile, single use absorbent polymeric wound matrix composed primarily of bioresorbable polyvinyl alcohol with a polymeric surface coating containing ionic and metallic silver. It has very low amounts of silver, with a maximum of 0.16 mg\u002Fin2. It absorbs wound fluid and forms a soft matrix that conforms to the wound surface and maintains a moist, wound-healing environment. The matrix contains silver only to prevent or minimize microbial growth within the matrix. Microlyte® Matrix is cleared by the U.S. Food and Drug Administration (FDA) under 510(k) \\[K153756\\] as a Class II device for the management of partial- and full-thickness wounds, including diabetic foot ulcers, venous stasis ulcers, pressure ulcers, surgical and traumatic wounds, and first- and second-degree burns and may be used over debrided and grafted partial-thickness wounds. It is fully synthetic and cleared as an antimicrobial barrier. The product is regulated under 21 CFR 878.4020 (dressing, wound,",[15],[30],"IP 2: Microlyte®",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":22},"IP 1: Membrane Wrap - Hydro","IP 1: Membrane Wrap - Hydro is a saline-hydrated allogeneic dual-layer amniotic membrane product that meets the criteria for regulation as a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) solely under section 361 of the Public Health Service (PHS) Act and 21 CFR part 1271. The amnion allograft is screened, processed, labeled, and distributed in a manner that prevents transmission of disease and is an allograft derived from donated human birth tissue. Membrane Wrap - Hydro amniotic membrane processing includes cleaning, rinsing, applying sterile mesh, folding to create a dual layer, drying then cutting, followed by hydration with sodium chloride solution 0.9%\" and sterilization using irradiation. Membrane Wrap - Hydro™ is intended to serve \"as a supportive barrier and provides protective coverage from the surrounding environment to acute and chronic wounds. Membrane Wrap-Hydro may be applied from the onset of the wound and for the duration of the wound.",[9],[36],{"name":37,"affiliation":5,"role":38},"Windy Cole, DPM","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":22,"email":44},"Marissa Docter, RN, BSN, MD","CONTACT","512-571-2966","mdocter@capsicure.com",[46,68,85,101,114,131,148],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"North Park Podiatry","RECRUITING","San Diego","California","92104","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-117.16472,32.71571,{"lat":58,"lon":57},[61,65],{"name":62,"role":42,"phone":63,"phoneExt":22,"email":64},"Marbella Lara","619-283-2097","marbella.npp1@gmail.com",{"name":66,"role":67,"phone":22,"phoneExt":22,"email":22},"Trent Brookshier","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":48,"city":70,"state":71,"zip":72,"country":52,"countryCode":53,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Solutions Medical Research","Coral Gables","Florida","33134",{"type":55,"coordinates":74},[75,76],-80.26838,25.72149,{"lat":76,"lon":75},[79,83],{"name":80,"role":42,"phone":81,"phoneExt":22,"email":82},"Liliana Lorenzo","305-425-1238","lorenzo@solutionsmedicalresearch.com",{"name":84,"role":67,"phone":22,"phoneExt":22,"email":22},"Francisco Jose Oliva",{"facility":86,"status":48,"city":87,"state":71,"zip":88,"country":52,"countryCode":53,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"NAR Medical and Research","Miami","33135",{"type":55,"coordinates":90},[91,92],-80.19366,25.77427,{"lat":92,"lon":91},[95,99],{"name":96,"role":42,"phone":97,"phoneExt":22,"email":98},"Lianne Batista","786-803-8986","lbatista@narmedicalresearchgroup.com",{"name":100,"role":67,"phone":22,"phoneExt":22,"email":22},"Julio Arronte",{"facility":102,"status":48,"city":87,"state":71,"zip":103,"country":52,"countryCode":53,"cosmosGeoPoint":104,"geoPoint":106,"contacts":107},"Nova Medical Services - Research Division LLC","33176",{"type":55,"coordinates":105},[91,92],{"lat":92,"lon":91},[108,112],{"name":109,"role":42,"phone":110,"phoneExt":22,"email":111},"Valmys Ortiz","786-715-9183","Valmys.Ortiz@novamedicalcare.com",{"name":113,"role":67,"phone":22,"phoneExt":22,"email":22},"Sandor Romero",{"facility":115,"status":48,"city":116,"state":117,"zip":118,"country":52,"countryCode":53,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Indiana University Health Methodist Hospital","Indianapolis","Indiana","46202",{"type":55,"coordinates":120},[121,122],-86.15804,39.76838,{"lat":122,"lon":121},[125,129],{"name":126,"role":42,"phone":127,"phoneExt":22,"email":128},"Bryce Hockman","317-278-2715","bbhockma@iu.edu",{"name":130,"role":67,"phone":22,"phoneExt":22,"email":22},"Mithun Sinha",{"facility":132,"status":48,"city":133,"state":134,"zip":135,"country":52,"countryCode":53,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"St. Louis Foot and Ankle, LLC","St Louis","Missouri","63128",{"type":55,"coordinates":137},[138,139],-90.19789,38.62727,{"lat":139,"lon":138},[142,146],{"name":143,"role":42,"phone":144,"phoneExt":22,"email":145},"Bonnie Weiss","314-596-9670","blsweiss.practicemanager@gmail.com",{"name":147,"role":67,"phone":22,"phoneExt":22,"email":22},"Raymond Abdo",{"facility":149,"status":48,"city":150,"state":151,"zip":152,"country":52,"countryCode":53,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Hope Vascular and Podiatry","Houston","Texas","77054",{"type":55,"coordinates":154},[155,156],-95.36327,29.76328,{"lat":156,"lon":155},[159,163],{"name":160,"role":42,"phone":161,"phoneExt":22,"email":162},"Jeena RoshanRaj","346-541-6421","jroshanraj@hcic.io",{"name":164,"role":67,"phone":22,"phoneExt":22,"email":22},"Brian Lepow",{"type":166,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[168],{"name":169,"class":170},"BioLab Holdings","INDUSTRY","100645480","campr-ii-rwe-trial-a-saline-hydrated-allogeneic-dual-layer-amniotic-membrane-product-or-a-synthetic-resorbable-polymeric-wound-matrix-to-a-coarsened-exact-matched-retrospective-control-cohort-of-hard-to-heal-dfus-and-vlus-100645480",false,"NCT07701590","CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs","A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-heal DFUs and VLUs","CAMPR-II","Inclusion Criteria:\n\n1. Male or female 18 years of age and older\n2. If a female is not currently pregnant or breastfeeding nor plans to become pregnant during the study and is either not of childbearing potential (defined as: postmenopausal \\[defined as amenorrhea for at least 1 year and serum follicle stimulating hormone (FSH) level \\>40 IU\u002FL\\], or surgically sterile \\[bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation at least 6 months prior to IP administration\\]), or is practicing one or more of the following medically acceptable methods of birth control throughout the study.\n\n   1. Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on subject's usual menstrual cycle period) before Screening\u002FRandomization Visit and must follow that product's package insert instructions including additional protection at times when hormonal contraceptive doses might be missed.\n   2. Total abstinence from sexual activities that can lead to pregnancy for at least 6 months prior to Screening\u002FRandomization Visit. Abstinence is acceptable when it is in line with the subject's preferred and usual lifestyle.\n   3. Intrauterine device\n   4. Vasectomized Partner (for at least 6 months)\n   5. Double-barrier method (condoms and clerical cap with spermicidal jellies or cream or condoms and diaphragm with spermicidal jellies or cream or condoms and contraceptive foam).\n3. Negative pregnancy test for all subjects of childbearing potential\n4. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of \\>4 weeks duration.\n5. No visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks\n6. Subjects' wound size is minimum of 2 cm2 and maximum of 24cm2\n7. If the subject has more than one eligible wound the largest wound will be selected (the index wound)\n8. Subject is able and willing to follow the protocol requirements\n9. Subject has signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to adhere to the study protocol or study visit schedule\n2. Pregnancy\n3. Child-bearing potential without appropriate contraception\n4. Lactation\n5. Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit.\n6. Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)\n7. The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety\n8. Known contraindications to the use of either IP1 or IP2\n9. The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics.","ALL","18 Years",{"count":182,"type":183},147,"ESTIMATED","INTERVENTIONAL",[186],"NA","CAMPR-II Trial: A multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a saline-hydrated allogeneic dual-layer amniotic membrane product or a synthetic, resorbable polymeric wound matrix to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs",[189,190,191],"Wound, Foot","Diabetic Foot Ulcer (DFU)","Venus Leg Ulcer",[193,194,191,195],"DFU","VLU","Diabetic Foot Ulcer","2026-07-13",{"date":198,"type":199},"2026-07-14","ACTUAL",{"date":201,"type":199},"2026-06-22",{"date":203,"type":183},"2026-12-20",{"name":5,"class":6},7]